Takeda Pharmaceutical Co.
Ltd.
(NYSE:TAK) on Friday revealed encouraging secondary data from two pivotal Phase 3 trials evaluating zasocitinib, its next-generation oral treatment for moderate-to-severe plaque psoriasis.
Presented at the 2026 American Academy of Dermatology Innovation Academy, the data highlight the drug's ability to clear skin in high-impact, difficult-to-treat areas compared to a placebo and an active comparator.
The findings build upon topline results from the LATITUDE PsO 3001 and 3002 studies.
